Pharma News

Keep updating your pharma knowledge
Cipla launches GLYCOHALE respule
19 Mar 2020

Cipla launches GLYCOHALE respule

Posted By

Cipla has annouced the introduction of Glycohale Respules. This helps Cipla to strengthen the Respiratory portfolio. Glycopyrrolate inhalation is indicated for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

GLYCOHALE respule is an anticholinergic medicine known as glycopyrrolate.

  • Anticholinergic medicines such as GLYCOHALE respule help the muscles around the airways in your lungs stay relaxed to prevent symptoms such as wheezing, coughing, chest tightness, and shortness of breath.
  • GLYCOHALE respule is used for maintenance treatment of COPD. COPD is a long-term (chronic) lung disease that includes chronic bronchitis, emphysema, or both.
  • GLYCOHALE respule is for long-term use and should be taken 2 times each day to improve symptoms of COPD for better breathing.
  • GLYCOHALE respule is not used to treat sudden or acute symptoms of COPD. Always have a short-acting beta2-agonist medicine (rescue inhaler) with you to treat sudden symptoms of COPD. If you do not have a rescue inhaler, contact your healthcare provider to have one prescribed for you.

Qualitative and Quantitative Composition

Each 1 ml ampoule contains:

Glycopyrrolate IP……………….…25mcg

Dosage Form(S) and Strength(S)

Glycopyrrolate Inhalation Solution is supplied as a sterile, clear, colorless, aqueous solution for inhalation in a unit-dose single-use LDPE respule. Each 1 mL respule contains 25 mcg of glycopyrrolate.

Leave a Reply

The reCAPTCHA verification period has expired. Please reload the page.

Upskill Your Pharma Knowledge

Explore Next Gen Learning

Case Studies & Caselets | Simulation Based Learning | E-Lectures | Online Self Competency Assessments

Thank You for Subscription!